Literature DB >> 25435270

PET-CT offers accurate assessment of tumour length in oesophageal malignancy.

K E Rollins1, E Lucas2, N Tewari3, E James4, S Hughes5, J A Catton3.   

Abstract

INTRODUCTION: Radiotherapy is increasingly used for both curative and palliative treatment of oesophageal malignancy. Accurate treatment depends on determining tumour location and length. This study assessed the value of PET-CT versus other staging modalities in determining tumour length.
MATERIALS AND METHODS: Oesophageal cancer patients who underwent staging with PET/CT and endoscopic ultrasound (EUS) in addition to their diagnostic upper GI endoscopy and subsequent surgical resection were assessed. PET/CT length was obtained retrospectively by using Hermes Hybrid Viewer™ with a 1-5 Standardised Uptake Value grey scale. An SUV of 5 was used as the cut off for determining length. Direct measurement by EUS and OGD were determined.
RESULTS: 53 patients underwent PET-CT, EUS, OGD and surgical resection for oesophageal cancer. Overall the correlation between PET-CT and histopathological length was strongest (Pearson r=0.5977, 95% CI 0.390-0.747) versus EUS (Pearson R=0.5365, 95% CI 0.311-0.705) and OGD (Pearson r=0.1574, 95% CI -0.118 to 0.410). After excluding tumours with a significant chemotherapy response, PET-CT length correlated significantly with histopathological length (R=0.5651, p=0.0005). In comparison, the correlation between histological length and EUS (R=0.4637, p=0.0057) measurement was less significant and this did not correlate with OGD (R=-0.1084, p=0.5417).
CONCLUSION: Tumour length estimated by PET-CT correlated most strongly with histopathological length of oesophageal malignancy and is the most accurate determinant of tumour length of all the staging modalities. This suggests a potential role for PET-CT in the planning of radiotherapy and resection, particularly when considering the practical limitations of EUS.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endoscopic ultrasound; Oesophageal malignancy; Oesophago-gastroduodenoscopy; PET/CT; Tumour length

Mesh:

Year:  2014        PMID: 25435270     DOI: 10.1016/j.ejrad.2014.10.014

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer.

Authors:  S Münch; M Oechsner; S E Combs; D Habermehl
Journal:  Radiat Oncol       Date:  2017-08-15       Impact factor: 3.481

Review 2.  Is endoscopic ultrasound examination necessary in the management of esophageal cancer?

Authors:  Tomas DaVee; Jaffer A Ajani; Jeffrey H Lee
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

3.  18-Fluorodeoxy-Glucose Positron Emission Tomography- Computed Tomography (18-FDG-PET/CT) for Gross Tumor Volume (GTV) Delineation in Gastric Cancer Radiotherapy

Authors:  Kinga Dębiec; Jerzy Wydmański; Izabela Gorczewska; Paulina Leszczyńska; Kamil Gorczewski; Wojciech Leszczyński; Andrea d’Amico; Michał Kalemba
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

4.  Follow up results of a prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer.

Authors:  Sweet Ping Ng; Jennifer Tan; Glen Osbourne; Luke Williams; Mathias A B Bressel; Rodney J Hicks; Eddie W F Lau; Julie Chu; Samuel Y K Ngan; Trevor Leong
Journal:  Clin Transl Radiat Oncol       Date:  2017-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.